Skip to main content
. Author manuscript; available in PMC: 2018 Jan 25.
Published in final edited form as: J Intern Med. 2014 Oct;276(4):352–363. doi: 10.1111/joim.12244

Table 2.

Placebo-subtracted decrease in HbA1c (%) with different SGLT2 inhibitors in DM subjects receiving various types of background therapy

Background
therapy		 Ipragliflozin Canagliflozin Dapagliflozin Empagliflozin
Drug-naïve −1.23 −1.03 −0.66 −0.69
Metformin −1.29 −0.93 −0.54 −0.71
Sulphonylurea −1.14 −1.03 −0.59 −0.60
Pioglitazone −0.88 NT −0.55 −0.61
Insulin NT −0.73 −0.55 −0.62

NT, not yet tested/reported.